Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines for universal health coverage. Lancet 2017;389:1880-1. [Ref.ID 101601]

Rejón R. Las aseguradoras de EE UU han logrado mejor precio que los gobiernos europeos para la cura de la hepatitis C . eldiario.es 2016:1. [Ref.ID 100694]

Dyer O. udge overturns ruling on patent after finding Merck lied to court. BMJ 2016;353:i3354. [Ref.ID 100428]

Anónimo. Hepatitis C combination drug may shorten duration of treatment to four weeks, mid-stage trial shows. DIA Daily 2016:3. [Ref.ID 100004]

Walker J. Patients struggle with high drug prices. Out-of-pocket costs for pricey new drugs leave even some insured and relatively affluent patients with hard choices on how to afford them. Wall St J 2016:1. [Ref.ID 99949]

Anónimo. Daclatasvir. Prescrire 2015;35:738-9. [Ref.ID 99846]

Anónimo. Lédipasvir + sofosbuvir. Prescrire 2015;35:732-8. [Ref.ID 99845]

Anónimo. Abordaje de la hepatitis C. ¿Tiempos para la esperanza?. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-10. [Ref.ID 99823]

Anónimo. Senate report criticizes Gilead for high price of hepatitis drug. DIA Daily 2015:2 de diciembre. [Ref.ID 99686]

Naggie S, Cooper C, Saag M, Workowski K, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13. [Ref.ID 99506]

McCarthy M. Lawsuit seeks access to data from hepatitis C drug trial. BMJ 2015;350:h3564. [Ref.ID 99222]

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015;385:1107-13. [Ref.ID 98987]

Foster GR. Shorter treatments for hepatitis C: another step forward?. Lancet 2015;385:1054-5. [Ref.ID 98983]

Anónimo. Hepatitis C: only a step away from elimination?. Lancet 2015;385:1045. [Ref.ID 98981]

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]

Anónimo. A 4-drug combination (Viekira Pak) for hepatitis C. Med Lett Drugs Ther 2015;57:15-7. [Ref.ID 98854]

Herman AO. State Medicaid programs seek discounts on pricey hepatitis C drugs. Physician's First Watch 2015:2 de febrero. [Ref.ID 98749]

Anónimo. FDA approves Viekira Pak to treat hepatitis C. U.S. Food and Drug Administration 2014:19 de diciembre. [Ref.ID 98390]

Anónimo. Another hepatitis C treatment recieves FDA approval. DIA Daily 2014:13 de octubre. [Ref.ID 98033]